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http://dx.doi.org/10.1016/j.jaci.2015.11.012Results: Activation of DP1, DP2, or both receptors on human
macrophages induced strong intracellular Ca21 flux, cytokine
release, and migration of macrophages. In a murine model of
LPS-induced pulmonary inflammation, activation of each PGD2
receptor resulted in aggravated airway neutrophilia, tissue
myeloperoxidase activity, cytokine contents, and decreased lung
compliance. Selective depletion of alveolar macrophages
abolished the PGD2-enhanced inflammatory response.
Activation of PGD2 receptors on human macrophages enhanced
the migratory capacity and prolonged the survival of
neutrophils in vitro. In human lung tissue specimens both DP1
and DP2 receptors were located on alveolar macrophages along
with hematopoietic PGD synthase, the rate-limiting enzyme of
PGD2 synthesis.
Conclusion: For the first time, our results show that PGD2
markedly augments disease activity through its ability to
enhance the proinflammatory actions of macrophages and
subsequent neutrophil activation. (J Allergy Clin Immunol
2016;137:833-43.)
Key words: D-type prostanoid receptor 1, D-type prostanoid recep-
tor 2/chemoattractant receptor–homologous molecule expressed on
TH2 cells, prostaglandin D2, hematopoietic prostaglandin D syn-
thase, macrophages, pulmonary inflammation, neutrophils
Prostaglandin (PG) D2, a lipid mediator from the arachidonic
acid/COX pathway, has been shown to play complex and often
opposing roles in the development and resolution of inflamma-
tion, which can be attributed to differential activation of its recep-
tors. PGD2 activates 2 G protein–coupled receptors, the D-type
prostanoid receptors (DPs) DP1 and DP2, with the latter also
known as chemoattractant receptor–homologous molecule ex-
pressed on TH2 cells.
1 At higher concentrations, PGD2 can also
signal through the thromboxane A2 receptor.
2,3 Although PGD2
exerts similar binding affinities toward the DP1 andDP2 receptors,
its metabolites, formed rapidly by enzymatic and nonenzymatic
pathways, can differentially induce DP2-mediated effects.
1
In patients with allergic diseases, the role of PGD2 has mostly
been associated with its release from activated mast cells and in-
duction of vasodilation. More recently, however, PGD2 has been
found to promote additional proinflammatory responses through
activation of DP2 receptors reflected by increased eosinophilic
infiltration into the lungs and skin of mice.4,5 Consequently,
DP2 antagonists were shown to ameliorate eosinophilic pulmo-
nary inflammation in murine ovalbumin-induced6 and house
dust mite–induced7 models, a rat Alternaria species–induced
model,8 and the setting of chronic allergic skin inflammation.9
Moreover, the DP2 antagonist CAY10471 ameliorated weight833
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DP: D-type prostanoid receptorHPGDS: Hematopoietic prostaglandin D synthaseKC: Keratinocyte-derived chemokineMDM: Monocyte-derived macrophagesMPO: MyeloperoxidasePG: ProstaglandinTX: Thromboxaneloss and intestinal inflammation in a dextran sodium sulfate–
induced colitis model inmice.10 In asthmatic patients induction of
hematopoietic prostaglandin D synthase (HPGDS), the rate-
limiting enzyme of PGD2 synthesis, was observed in the epithelial
compartment,11 and PGD2 levels in bronchoalveolar lavage
(BAL) fluid correlated positively with the severity of the dis-
ease.12 DP2/chemoattractant receptor–homologous molecule ex-
pressed on TH2 cell antagonists was found to have some effects
in allergic rhinitis,13 allergic conjunctivitis,14 eosinophilic esoph-
agitis,15 and bronchial asthma.16,17
Macrophages are essential in pulmonary inflammatory diseases
bymaintaining tissue homeostasis andmounting rapid responses to
exogenous and endogenous stimuli. Because they are the main
source of proinflammatory cytokines, such as TNF-a, IL-1b, and
IL-6, their role in inflammation is pivotal.18 Acute lung injury
(ALI) or its more severe clinical manifestation, acute respiratory
distress syndrome (ARDS), is a pulmonary inflammatory disease
that can lead to respiratory failure. Pulmonary complications in
this disease are mainly attributed to rapid neutrophil infiltration
into the alveolar space,19 subsequent edema formation, and
dysfunction of the involved cell types, including epithelial cells,20
endothelial cells,21 and macrophages.22-24 Several studies have
made it clear that macrophages orchestrate neutrophilic infiltration
and thus strongly modulate the outcome of ARDS.23-27
Stimulatedby the dominant physiologic roleofPGD2 in the lung,
we hypothesized that PGD2 might govern disease activity and pro-
gression by acting on lung macrophages. Previous studies revealed
anti-inflammatory effects of the PGD2 metabolite 15d-PGJ2 acting
through peroxisome proliferator–activated receptor g in RAW
264.7macrophages28 and demonstrated the expression of PGD2 re-
ceptors on human monocytes,29 whereas the role of PGD2 in regu-
lation of macrophage function has not been assessed yet.METHODS
Detailed description of ethical permits, materials, and procedures is provided
in theMethods section in this article’s Online Repository atwww.jacionline.org.Isolation of peripheral blood polymorphonuclear
neutrophils and PBMCs
Human peripheral blood polymorphonuclear cells and PBMCswere isolated
from healthy donors independent of sex and age, as described previously.30Differentiation from monocytes to macrophages
Human peripheral blood monocytes isolated from healthy donors were
differentiated to human monocyte-derived macrophages (MDMs) for 7 to10 days with 20 ng/mL human recombinant macrophage colony-stimulating
factor.
Live cell fluorescent Ca21 imaging
Macrophages were loaded with 2 mmol/L Fura-2/AM. Fluorescence
images were obtained with alternate excitation at 340 and 380 nm, and
emitted light was collected at 510 nm. Intracellular calcium levels were
calculated, as previously described.31
Monocyte Ca21 flux
Ca21 flux was measured by means of flow cytometry, as previously
described.30
Neutrophil apoptosis
Neutrophil survival was assessed by using Annexin V/propidium iodide
staining, as described previously.32
Neutrophil and macrophage chemotaxis
Neutrophils were placed in the upper compartment of a Transwell chamber
(Corning, Inc, New York, NY) in the absence or presence of MDMs. After
1 hour, neutrophils that migrated to the bottomwell were collected, suspended
in 150 mL of fixative solution, and enumerated by means of flow cytometric
analysis.33 Migration of human MDMs was assessed by using Transwell in-
serts, as described previously.30
Flow cytometric staining
The following antibodies and concentrations were used: DP2 (20 mg/mL),
DP1 (20 mg/mL), anti-mouse MHC class II (2.5 mg/mL), anti-mouse Siglec-F
(5 mg/mL), anti-mouse CD3ε (5 mg/mL), anti-mouse B220 (2 mg/mL), and
anti-mouse CD11c (2 mg/mL) antibodies.LPS-induced lung injury
Pulmonary inflammation was induced in 8- to 10-week-old BALB/c mice
by means of intranasal application of 1 mg/kg LPS. Agonists or antagonists
were applied 24 hours before LPS application subcutaneously every 12 hours.
Unless stated otherwise, mice were killed 4 hours after LPS administration.Myeloperoxidase assay
Myeloperoxidase (MPO) activity was determined, as described
previously.34BAL protein content
BAL protein concentrations were measured by using a bicinchoninic acid
protein assay kit (Thermo Fisher Scientific, Rockford, Ill), according to the
manufacturer’s protocol.
Vascular permeability in lung tissue was assessed by using Evans blue dye
extravasation after 60 minutes of circulation. Evans blue protein leak was
determined, as described in the Methods section in this article’s Online
Repository.Murine lung histology
Paraffin-embedded murine lungs were cut (5-mm sections), deparaffinized,
and immunostained with anti-Ly6G and hematoxylin.Isolation of murine alveolar and interstitial
macrophages
Alveolar and interstitial macrophages were isolated from BAL fluid, as
described in the Methods section in this article’s Online Repository.
FIG 1. PGD2 receptors DP1 and DP2 are expressed on macrophages and induce Ca
21 flux and migration. A,
Flow cytometric histograms of DP2 and DP1 staining (filled histograms) on MDMs, respectively. B, Immuno-
histochemistry of healthy human lung tissue showing DP2- and DP1-positive alveolar macrophages (ar-
rows). C, Representative Ca21 responses of MDMs over time. D, MDM migration toward PGD2 is blocked
by DP1- and DP2-specific antagonists (n 5 4-5). *P < .05 and ***P < .001.
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Three hundred micrograms (in 60 mL volume) of clodronate or control
liposomes were intranasally applied to mice 24 hours before LPS challenge.35Cytokine measurements
Cytokine levels were determined by using either a multianalyte
immunoassay (Bender Medsystems, Vienna, Austria), ELISA (PeproTech,
Rocky Hill, NJ), or the ProcartaPlex Mouse Cytokine Kit (eBioscience, San
Diego, Calif).Immunohistochemistry of human lung tissue
Human paraffin-embedded lung samples were stained with anti-DP2
(1:200), anti-DP1 (1:100), or anti-HPGDS (1:200) antibodies.Lipid mediator analysis
PGD2, PGE2, TXB2, 12S-hydroxy-5Z,8E,10E-heptoadectrienoic acid, and
6-keto-PGF1a were analyzed by using liquid chromatography–tandem mass
spectrometry, as previously published36 and as described in the Methods sec-
tion in this article’s Online Repository.
FIG 2. PGD2 acting through DP1 and DP2 promotes neutrophil influx into lungs and aggravates airway hy-
perreactivity. A and B, Neutrophil infiltration is increased in animals pretreated with PGD2 (Fig 2, A) or DP1-
and DP2-selective agonists (Fig 2, B). C-F, PGD2 pretreatment increases Ly6G-positive neutrophil infiltration
in the peribronchial and alveolar space (representative pictures, scale bar 5 50 mm; Fig 2, C), MPO activity
(Fig 2, D), Evans blue dye extravasation (Fig 2, E), and airway hyperreactivity (vs vehicle/LPS; Fig 2, F).
*P < .05, **P < .01, and ***P < .001.
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Decreased lung compliance caused by pulmonary edema and atelectasis is
a hallmark of human ALI/ARDS and a preferred readout in mouse models.37
Therefore mouse lung function was determined by using the flexiVent system
(SCIREQ, Montreal, Quebec, Canada), as described previously.38Statistical analysis
Data were analyzed by using either the Student t test, 1-way ANOVA, or 2-
way ANOVA, followed by the Bonferroni or Dunnett posttest, with GraphPad
Prism software (version 5.04; GraphPad Software, La Jolla, Calif). In vitroexperiments were performed in duplicates, with n numbers indicating biolog-
ical replicates with cells from different donors. P values of less than .05 were
considered significant.RESULTS
DP1 and DP2 are expressed on human macrophages
and induce Ca21 signaling
We first set out to elucidate whether PGD2 receptors are ex-
pressed on human monocytes and macrophages and found that
FIG 3. Blocking of endogenous PGD2 ameliorates LPS-induced neutrophil influx into the alveolar space and
pulmonary tissue. A and B, DP1 antagonist reduced neutrophil counts in the bronchoalveolar space (Fig 3,
A), whereas DP2 antagonist reduced MPO activity (Fig 3, B; n 5 6-9). *P < .05 versus vehicle. C, Lipid medi-
ators in BAL fluid 4 hours after vehicle or LPS treatment were quantified by using liquid chromatography–
tandem mass spectrometry (n 5 4). HHTrE, 12S-hydroxy-5Z,8E,10E-heptoadectrienoic acid. *P < .05 versus
vehicle.
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and see Fig E1 in this article’s Online Repository at www.
jacionline.org). Interestingly, expression of both receptors
increased during differentiation of MDMs, with DP2 expression
being more abundant than DP1 expression in both monocytes
and macrophages (see Fig E1). Next, we probed for DP1 and
DP2 expression in human lung tissue with different pathologies
(see Table E1 in this article’s Online Repository at www.
jacionline.org). Both were highly and consistently expressed on
human alveolar macrophages (Fig 1, B) because 60% to 75% of
alveolar macrophages were positively stained for both DP1 and
DP2 independent of the underlying disease (see Figs E2 and E3
in this article’s Online Repository at www.jacionline.org). This
expression pattern suggested a possible role for the PGD2-DP1-
DP2 axis in the modulation of macrophage biology in patients
with pulmonary diseases.
Then we sought to determine the biological activities of DP1
and DP2 in vitro. Ca
21 imaging revealed that superfusion of hu-
man MDMs with 1 mmol/L PGD2 led to a strong release of intra-
cellular calcium (Fig 1, C, and see Fig E4, A, in this article’s
Online Repository at www.jacionline.org), whereas human
monocytes showed no Ca21 response to PGD2 stimulation (see
Fig E5 in this article’s Online Repository at www.jacionline.
org). Both DP2- and DP1-selective agonists (13,14-dihydro-15-
keto PGD2, and BW245C, respectively; 1 mmol/L) were likewiseable to elicit Ca21 flux, although to a lesser extent than PGD2 (Fig
1, C, and see Fig E4, A). In agreement with this observation,
blockade of either DP2 (CAY10471, 10 mmol/L) or DP1
(MK0524, 10 mmol/L) slightly decreased, whereas simultaneous
antagonism of both receptors abolished the PGD2-induced Ca
21
signal (see Fig E4, B and C). Ca21 release induced by both
PGD2 and 13,14-dihydro-15-keto prostaglandin D2 (DK-PGD2)
was prevented by overnight incubation with pertussis toxin
(100 ng/mL), indicating involvement of Gai heterotrimers in
this process (see Fig E4, D and E).PGD2 induces migration of macrophages through
DP1 and DP2 and enhances TNF-a secretion
We next evaluated the chemotactic potential of PGD2 toward
MDMs by using Transwell inserts, followed by enumeration of
fluorescently labeled cell nuclei of the migrated cells on the
lower surface of the filter (see Fig E6, B). We found that
PGD2 exerted a concentration-dependent chemotactic activity
toward MDMs, with the highest responses observed at
100 nmol/L (Fig 1, D, and see Fig E6, A, in this article’s Online
Repository at www.jacionline.org). This could be partially
blocked by either the DP2- or DP1-specific antagonist
(CAY10471 or MK0524, 1 mmol/L, respectively; Fig 1, D). In-
hibition of both receptors completely abolished the migratory
FIG 4. Macrophage depletion prevents the proinflammatory effect of PGD2 on neutrophil recruitment. A,
Neutrophil numbers in BAL fluid. B, MPO activity in lung tissue. *P < .05, **P < .01, and ***P < .001. C,
Macrophage depletion prevents reduction in lung function induced by PGD2 (n 5 6-8). *P < .05, **P < .01,
and ***P < .001 versus vehicle/LPS.
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shown to be critical in mediating macrophage migration toward
LPS in a murine model,39 we hypothesized that PGD2 could
alter the LPS-induced cytokine secretion from MDMs.
Although almost no TNF-a was detectable in the supernatants
of vehicle-treated cells, LPS stimulation (100 ng/mL) induceda strong release of the proinflammatory cytokine. Indeed, this
response was markedly enhanced in cells pretreated with
PGD2 or DK-PGD2 (see Fig E6, C). Although the DP1-specific
agonist BW245C was not able to induce changes in TNF-a
secretion, involvement of both DP1 and DP2 receptors in the
PGD2 response is still likely because only antagonism of both
FIG 5. PGD2 receptor activation on MDMs increases neutrophil migration toward IL-8 (A and B) and pro-
longs neutrophil survival (C and D) in vitro. Fig 5, A, C, and D: n 5 5-10; Fig 5, B: n 5 3-5. *P < .05 and
**P < .01 versus vehicle. PI, Propidium iodide.
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crease in TNF-a secretion.Endotoxin-induced lung injury is aggravated by
PGD2
Prompted by these observations, we investigated the effect of
PGD2 in an in vivo model of pulmonary inflammation. Here
neutrophil infiltration is a main pathogenic feature that essentially
depends on macrophage function.23 LPS significantly increased
neutrophil influx into the bronchoalveolar space after 4 hours of
treatment. Of particular interest, this effect was almost doubled
when PGD2 (5 mg/kg) was administered subcutaneously before
LPS challenge (Fig 2, A). Selective DP1 and DP2 agonists induced
an even more pronounced response; in detail, the selective DP2
agonist DK-PGD2 (5 mg/kg) enhanced neutrophil influx by 2.5-
fold and the DP1 agonist BW245C (5mg/kg) enhanced neutrophil
influx by 2.3-fold (Fig 2, B). Histologically, the inflammatory
state of the lungs was indicated by dense Ly6G-positive neutro-
phil infiltrates in the bronchiolar region, with disturbed alveolar
morphology in LPS-treated animals. When PGD2 was adminis-
tered before LPS treatment, even more Ly6G-positive neutrophils
were found around the bronchioli accompanied by neutrophil in-
filtrates in the alveolar space, which was largely absent in vehicle/
LPS-treated mice (Fig 2,C, and see Fig E7, A, in this article’s On-
line Repository at www.jacionline.org). MPO activity, a marker
for lung inflammation, was likewise increased depending on the
applied dose of PGD2 (Fig 2, D). These observations werereflected by increased protein content in the BAL fluid in
PGD2-treated animals (see Fig E7, B), as well as enhanced Evans
blue extravasation in the lung tissue that depended on both DP1
and DP2 (Fig 2, E). It is noteworthy that the capacity of PGD2
to increase neutrophil recruitment was sustained after 24 hours
(see Fig E7, C). Only minor alterations were found in the number
of other cell types, such as monocytes, macrophages, lympho-
cytes, and eosinophils (see Fig E8 in this article’s Online Repos-
itory at www.jacionline.org). The observation that PGD2
aggravated pulmonary inflammation was also reflected by a
decrease in lung function. In these experiments we found that
LPS alone caused hyperresponsiveness to methacholine with
respect to airway resistance and compliance (Fig 2, F), which
was further accentuated after combined treatment of mice with
PGD2 and LPS (Fig 2, F). In all experimental readouts, including
cell infiltration into the alveolar space, MPO activity, and lung
function, PGD2 treatment in the absence of LPS had no effect
(data not shown).Blocking of endogenous PGD2 reduces neutrophilic
infiltration into the lungs
Mice were pretreated with the PGD2 receptor antagonists
MK0524 or CAY10471 (5 mg/kg) followed by LPS challenge
to delineate the pathogenic role of endogenous PGD2. Analysis
of BAL cells revealed that the DP1 antagonist MK0524 reduced
endotoxin-induced neutrophilia (Fig 3, A), whereas the DP2
antagonist CAY10471 reduced MPO activity (Fig 3, B). Next,
FIG 6. Increased numbers of HPGDS-expressing cells in lungs of patients
with ARDS. Representative immunohistochemical staining of human lung
samples showing positive cells for HPGDS (brown) in a control subject (A)
and a patient with ARDS (B). Stainings are representative pictures of 5 pa-
tients and control subjects. Note the high amount of HPGDS found in alve-
olar macrophages. Bar 5 100 mm.
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and LPS-treated animals and found that there was a marked in-
crease in PGD2 levels in the latter (Fig 3, C). In agreement with
previous findings, PGE2 levels also increased, as did TXB2 and
12S-hydroxy-5Z,8E,10E-heptoadectrienoic acid levels.We could
not detect any significant changes in PGI2 levels (estimated
through its metabolite 6-keto-PGF1a).PGD2 treatment enhances proinflammatory
cytokine release in vivo and in vitro
In addition to prostanoids, increased keratinocyte-derived
chemokine (KC) and monocyte chemotactic protein 1 levels
were observed in the cell-free BAL fluid of LPS-treated mice.
Importantly, the increase in levels of these chemokines was
significantly stronger in PGD2-treated animals (see Fig E9, A, in
this article’s Online Repository at www.jacionline.org). To deter-
mine whether macrophages were responsible for the increased
release of these chemokines, we isolated alveolar and interstitial
macrophages and mimicked the in vivo model. Both alveolar andinterstitial pulmonary macrophages increased secretion of the
neutrophil chemoattractant KC when pretreated with PGD2 (see
Fig E9, B and C), implicating macrophages as the cell type
responsible for the enhanced neutrophil recruitment in vivo. Inter-
estingly, monocyte chemotactic protein 1 secretion by alveolar
and interstitial macrophages was influenced by neither LPS nor
PGD2 treatment (see Fig E9, B and C).Macrophage depletion prevents the increased
inflammatory response mediated by PGD2
To highlight the role of macrophages in the PGD2-induced
enhancement of pulmonary inflammation, we next selectively
reduced alveolar macrophage counts in the pulmonary LPS
model. Intranasal application of 300 mg of clodronate led to a
marked reduction of macrophage counts by approximately 70%
throughout the groups (see Fig E10 in this article’s Online Repos-
itory at www.jacionline.org). This dose was chosen to avoid
proinflammatory responses caused by clodronate and/or lipo-
somes themselves, which were observed at higher doses (data
not shown). In animals that had received control liposomes,
LPS treatment led to neutrophil recruitment into the bronchoal-
veolar space, which was again further enhanced when the animals
were pretreated with PGD2 or any of the specific agonists for DP1
andDP2. After reduction of alveolarmacrophage counts, LPS still
enhanced neutrophil counts in the lungs, suggesting that 30% re-
sidual macrophages were sufficient to induce lung neutrophilia,
but no further increase in neutrophil counts was seen in PGD2-,
DK-PGD2–, or BW245C-treated animals (Fig 4, A, and see Fig
E11 in this article’s Online Repository at www.jacionline.org).
Concomitant to decreased alveolar neutrophil counts, the
PGD2-induced increase in MPO activity, as well as compromised
lung function, were reversed by alveolar macrophage reduction
(Fig 4, B and C).PGD2 receptor activation on macrophages
modulates neutrophil function
In vitro neutrophil migration assays were performed in the
presence of humanMDMs treated with vehicle or PGD2 to further
clarify the mechanisms through which PGD2 receptor activation
on macrophages augmented the LPS-induced neutrophil recruit-
ment. In this coculture experiment PGD2-treated macrophages
enhanced the migration of neutrophils when compared with basal
neutrophil migration in the presence of untreated MDMs (Fig 5,
A). This effect did not depend on IL-8 concentrations because
PGD2 treatment of MDMs enhanced the basal migratory capacity
and IL-8–induced migration of neutrophils alike. Importantly,
neutrophil migration was unaffected by PGD2whenmacrophages
were absent (Fig 5, B). Therefore PGD2 does not exert its effect
through direct stimulation of neutrophils but rather through a
macrophage-dependent pathway. In addition to migration, we
monitored neutrophil survival in further coculture experiments.
MDMs grown on 48-well plates were treated with vehicle or
PGD2 24 hours before neutrophils were added. Neutrophil
apoptosis was monitored over 24 hours. The portion of viable
neutrophils (Annexin V/propidium iodide negative) was higher
when macrophages were treated with PGD2 (Fig 5, C). Impor-
tantly, this effect was not due to enhanced macrophage phagocy-
tosis of apoptotic/necrotic neutrophils because neutrophil
numbers did not change throughout the experiment (see Fig
J ALLERGY CLIN IMMUNOL
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Furthermore, neutrophils cultivated without macrophages did
not react to PGD2 and showed the same survival rate as in the
presence of vehicle (Fig 5, D). These data show that PGD2 recep-
tor activation on macrophages profoundly influences neutrophil
function by enhancing their migratory capacity and survival.Cells expressing hematopoietic PGD2 synthase are
abundant in lungs of patients with ARDS
We finally examined whether levels of HPGDS, the rate-
limiting enzyme responsible for the production of PGD2, differed
in patients with ARDS and control subjects. Indeed, immunohis-
tochemistry revealed that, compared with control lung samples
(Fig 6, A), there was a clear increase in the number of cells highly
expressing HPGDS in patients with ARDS (Fig 6, B). Moreover,
although 50% to 60% of macrophages, as identified by means of
morphology, were positive for HPGDS, this value increased to
85% to 95% in lung sections from patients with ARDS.DISCUSSION
In this study we propose a novel role for PGD2 and its corre-
sponding receptors in pulmonary inflammation. Here, for the first
time, we show that human macrophages express active DP1 and
DP2, which are associated with alterations in cytokine profiles
and migratory responses, factors that contribute greatly to inflam-
mation in pulmonary diseases. First, we confirmed basal expres-
sion of PGD2 receptors on monocytes,
29 but we also showed an
upregulation that was more pronounced in the expression of
DP2 than DP1 during differentiation to macrophages. Further-
more, we were able to demonstrate that both PGD2 receptors
are functional on human macrophages: not only did macrophages
themselves migrate toward PGD2, but the PG also stimulated the
interaction of macrophages with neutrophils, thereby supporting
neutrophil migration and survival. This finding might be ex-
plained by the increased production of cytokines after PGD2 stim-
ulation of macrophages prompted by DP1/DP2-mediated Ca
21
flux.
Previous reports suggested that DP1- andDP2-mediated actions
oppose each other, being anti-inflammatory and proinflammatory,
respectively.10,40 Such divergent actions of PGD2 have not been
observed here because we could show that on human MDMs, se-
lective activation of both receptors increases intracellular free
Ca21 levels and induces migration. Furthermore, these responses
were only partially inhibited by either selective antagonist, and
only blockade of DP1 along with DP2 was sufficient to abolish
the PGD2-induced activation of macrophages. In this respect
PGD2 receptors on macrophages differed from other cell types,
such as eosinophils, where these receptors engage in a crosstalk
and both are needed for the complete functional response,41 and
bronchial epithelial cells, which express DP2 but not DP1.
11
We also observed DP1 and DP2 expression on human macro-
phages in the lung, both in the healthy state and in several patho-
logic conditions, from organizing pneumonia to diffuse alveolar
damage. Moreover, it was mainly the macrophages themselves
that were positive for the PGD2-synthesizing enzyme HPGDS
in the lungs of patients with ARDS. Although upregulation of
HPGDS has up to now mostly been described as a consequence
of increased numbers of epithelial and submucosal mast cells,42our finding proposes a new important role for PGD2 in the regu-
lation of macrophages in the lung.
Next, we investigated the biological role of PGD2 in lung path-
ophysiology in vivo and used a murine, LPS-induced lung injury
model that relies largely on functional macrophages.22,23 As pre-
dicted by our in vitro data, systemic application of PGD2, acting
through both DP1 and DP2, aggravated LPS-induced lung pathol-
ogy in several ways by (1) increasing neutrophil influx into the
airways, (2) promotingMPO activity in lung tissue, (3) increasing
cytokine levels, and (4) impairing lung function. Thus PGD2 en-
hances neutrophilic inflammatory responses in the presence of
disease-activating triggers. In parallel with increased levels of
PGD2 in the BAL fluid of LPS-treated animals, TXB2 levels
also increased. This upregulation of the TX pathway can further
substantiate our finding of DP2 activation in pulmonary inflam-
mation because we previously identified the TX metabolite 11-
dehydro-TXB2 as a full agonist for DP2.
43 Finally, we provided
evidence that these PGD2 responses essentially depended onmac-
rophages because murine alveolar macrophages were a rich
source of the neutrophil chemoattractant KC and macrophage
depletion reversed the ability of PGD2 to enhance lung inflamma-
tion. Two types of macrophages can be found in the lungs: alve-
olar and interstitial macrophages. Both are long-lived resident
cells that orchestrate tissue homeostasis and can react rapidly to
endogenous and exogenous stimuli, thus forming a first line of de-
fense,22 and both seemed to respond to PGD2 when KC secretion
was analyzed. Human cell studies, which we conducted in paral-
lel, identified 2 novel mechanisms of how PGD2 receptor activa-
tion on macrophages can regulate neutrophil function, namely
enhanced migratory capacity and survival of the latter. A recent
study showed that activated TH2 cells in response to PGD2 treat-
ment react with secretion of IL-6 and GM-CSF at levels that are
able to modulate neutrophil functions.44 Our data strongly sug-
gest that this mechanism is not restricted to TH2 cells but also ap-
plies to macrophages. One could speculate that type 2 activated
macrophages would be even more susceptible in this respect.
Finally, using the same mouse model, we could also demon-
strate a clear proinflammatory role of endogenous PGD2. Block-
ing of endogenous PGD2 either by DP1- or DP2-specific
antagonists ameliorated the inflammatory response, although in
a differential manner. On the one hand, the DP1-specific antago-
nist MK0524 decreased neutrophilia in the bronchoalveolar
space. On the other hand, the DP2-specific antagonist
CAY10471 markedly reducedMPO activity measured in lung tis-
sue. One reason for that discrepancy might be that here we are
looking at 2 different lung compartments. Neutrophils migrate
from the blood through the interstitium into the alveolar space,
and the 2 receptors might play different roles in this process,
such as DP2 regulating neutrophil recruitment from the blood to
the tissue and DP1 promoting alveolar evasion of neutrophils.
Alongwith the increase in PGD2 levels in the BAL fluid, these ob-
servations clearly highlight endogenous PGD2 in the develop-
ment of experimental pulmonary inflammation.
Recently, it was shown that mice lacking the DP1 receptor
display aggravated neutrophil influx and increased mortality in
experimental ALI.45 Although this study seemingly contradicts
our results, several experimental details make a direct comparison
difficult. First, the authors used almost 4 times higher doses of
LPS and observed the ensuing effects for 3 days. Second, DP1
was knocked out unconditionally, so that mice might have expe-
rienced compensational mechanisms, such as an upregulation of
J ALLERGY CLIN IMMUNOL
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tage of our study is the use of pharmacologic approaches, which
lends our findings clear translational potential toward clinical
application.
Collectively, we propose that the PGD2-DP1-DP2 axis on mac-
rophages is of pivotal importance in regulating inflammatory re-
sponses, and thus also in tissue damage, by triggering and
maintaining a proinflammatory environment. Given the involve-
ment of both PGD2 receptors in macrophage regulation, recently
developed dual DP1/DP2 antagonists
46 appear to be a promising
approach to treating distinct inflammatory diseases that involve
macrophage activation and neutrophil accumulation in the lung.
Key messages
d DP1 and DP2 are expressed and functionally active on iso-
lated MDMs and pulmonary macrophages.
d PGD2 receptor activation of macrophages promotes their
interaction with neutrophils and enhances neutrophil
function.
d The presence of hematopoietic PGD synthase, DP1, and
DP2 in macrophages highlights a novel role for PGD2 in
pulmonary inflammation.
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